Literature DB >> 1902285

Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments.

V Allegra1, G Mengozzi, A Vasile.   

Abstract

The study was carried out in order to evaluate in maintenance hemodialysis (MH) patients: (1) the reliability of serum ferritin (SF) measurement in iron deficiency diagnosis and therapy; (2) the possibility to improve iron stores assessment through laboratory indexes routinely used in clinical practice; (3) the most effective iron deficiency treatment. After a preliminary assessment of SF reference values in 250 healthy volunteers, we studied 72 MH patients divided into three groups according to their SF baseline values: high (group A), normal (group B), low (group C) (normal range 19-191 ng/ml). Each group was further divided into three subgroups receiving three different iron treatments for 6 months: (1) oral administration of 67.5 mg/day of Fe3+ as Fe-ferritin (subgroups A1, B1, C1); (2) oral administration of 60 mg/day of Fe3+ as Fe-chondroitin sulfate (subgroups A2, B2, C2); (3) i.v. administration at the end of each dialytic session of 31 mg of Fe3+ as Fe-gluconate-Na (subgroups A3, B3, C3). The response to the iron therapy was considered positive when the hemoglobin (Hb) and the hematocrit (Ht) increased to greater than or equal to 15% of the baseline values. The rate of positive responses in each subgroup was as follows: A1 0/5, A2 0/5, A3 0/7, B1 2/10, B2 1/6, B3 5/11, C1 1/7, C2 3/7, C3 10/16. We concluded that SF values above 191 ng/ml allow to exclude iron deficiency whereas SF values less than or equal to the normal range are inadequate. In an attempt to improve diagnostic sensitivity we divided patients of subgroup B3 and C3 into responders (R) and nonresponders (NR).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902285     DOI: 10.1159/000186246

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region.

Authors:  Rodolfo F Rivera; Davide Guido; Lucia Del Vecchio; Enzo Corghi; Marco D'Amico; Corrado Camerini; Donatella Spotti; Andrea Galassi; Claudio Pozzi; Giovanni Cancarini; Giuseppe Pontoriero; Francesco Locatelli
Journal:  J Nephrol       Date:  2015-12-29       Impact factor: 3.902

Review 2.  Safety aspects of parenteral iron in patients with end-stage renal disease.

Authors:  G Sunder-Plassmann; W H Hörl
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

3.  Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin.

Authors:  James B Post; Barry M Wilkes; Michael F Michelis
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

4.  Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use?

Authors:  K P Morris; S Watson; M M Reid; P J Hamilton; M G Coulthard
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

5.  Iron therapy in the pediatric hemodialysis population.

Authors:  Bradley A Warady; Annamaria Kausz; Gary Lerner; Eileen D Brewer; Vimal Chadha; Carlo Brugnara; Naomi V Dahl; Sandra L Watkins
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

6.  Parenteral versus oral iron therapy for adults and children with chronic kidney disease.

Authors:  Emma L O'Lone; Elisabeth M Hodson; Ionut Nistor; Davide Bolignano; Angela C Webster; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2019-02-21

7.  Chapter 2: Use of iron to treat anemia in CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-08

8.  FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.

Authors:  Iain C Macdougall; Andreas H Bock; Fernando Carrera; Kai-Uwe Eckardt; Carlo Gaillard; David Van Wyck; Bernard Roubert; Jacqueline G Nolen; Simon D Roger
Journal:  Nephrol Dial Transplant       Date:  2014-06-02       Impact factor: 5.992

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.